Precision Medicine


Multiplex Tissue Analysis + Digital Pathology in Clinical Research – A Summary of ASCO 2021 Findings

Background The range of technologies that enable multiplex tissue analysis (MTA) and digital pathology (DigPath) are rapidly growing and entering the clinical research space, providing new means of characterizing the

COVID’s Effect on mRNA Assets, Part II: Experience (and Quality) Matters

  With renewed interest in disparate applications and the subsequent flood of newcomers to mRNA asset development, the focus on quality and experience with regard to mRNA is more important

The Galaxy’s Guardians with Dr. Chris Mason

I recently had a chance to sit down for a really fun conversation with my friend Dr. Chris Mason. Chris is a professor at Weill Cornell Medicine, and he works

Navigating Companion Diagnostics (CDx) – Multiple Stakeholders, Many Goals

Background Companion diagnostic (CDx) tests are a foundational tool in precision medicine, helping ensure only the right patients receive the right therapies. The past several years have seen an explosion

DeciBio’s Q&A with Omead Ostadan — President & COO of Seer, Inc.

Following Seer’s first earnings call as a public company, we had the opportunity to sit down and discuss Seer’s technology and the proteomics market with Omead Ostadan. You can find

COVID’s Effect on mRNA Assets, Part I: Vaccines & Delivery

  With a global pandemic to fight, the speed, efficacy, and efficiency of mRNA vaccine research, development, and manufacturing have been proven invaluable. While the Moderna (mRNA-1273) and BioNTech (Comirnaty)

AGBT 2021 Catch-Up with Jeffrey Rosenfeld

  Jeffrey Rosenfeld, Ph.D. has extensive experience in genomics and bioinformatics. Over his 15-year career in genomics, he has worked on a wide range of biological and genetic projects including

AGBT 2021: DeciBio Quick Highlights – Spatial Profiling Takes Center Stage

AGBT 2021: DeciBio Quick Highlights – Spatial Profiling Takes Center Stage My Livingroom, Home March 4, 2021 – AGBT’s 21st edition was in sharp contrast to last year’s, and about

Update on the Adoption And Utilization of Emerging Precision Medicine Biomarkers and Technologies in Routine Clinical Care

At DeciBio Consulting, our mission is to provide market intelligence and insights to advance precision medicine.  To this end, we track this space closely, especially the field of precision oncology,